BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026 BeyondSpring (NASDAQ: BYSI) will present a poster at the AACR Annual Meeting 2026 in San Diego on April 21, 2026. The poster, titled Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates, is scheduled for 2:00–5:00 PM PT in Poster Section 8, Poster Board 16 (Poster 5597).The presentation appears in the Immunology session category under "T Cell Engagers 2 / Antibody-Drug Conjugates 1" and lists Yingjuan June Lu and colleagues as presenters/authors.

#BYSI BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

www.stocktitan.net/news/BYSI/beyond-spring-...

BeyondSpring Files 2025 Annual Report on Form 10-K BeyondSpring (NASDAQ:BYSI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the SEC on March 25, 2026.The filing includes the company’s audited consolidated financial statements and is available on the SEC website and the company’s investor site. Shareholders may request a free hard copy from Investor Relations.

#BYSI BeyondSpring Files 2025 Annual Report on Form 10-K

www.stocktitan.net/news/BYSI/beyond-spring-...

Lung cancer drug shows survival gain as BeyondSpring readies new trial Phase 3 data showed a 2.5-month median survival gain and sharply lower severe neutropenia. BeyondSpring ended 2025 with $12.6M cash.

#BYSI BeyondSpring Reports 2025 Year-End Financial Results

www.stocktitan.net/news/BYSI/beyond-spring-...

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD

#BYSI BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BYSI/beyond-spring-...

Trade Alerts, Monday November 3, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend according to ave directional index, Mon Nov 3rd - #URGN #MDXG #III #EVTV #BYSI #ADTN #PDS #MD #FRGE #CMRE - More: crystalequityresearch.com/trade-alerts... - #smallcap

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure BeyondSpring (NASDAQ: BYSI) has published significant clinical results in Med (Cell Press) demonstrating the effectiveness of Plinabulin in combination with radiation and checkpoint inhibitors for cancer treatment. The study showed an overall response rate (ORR) of 23% and a disease control rate (DCR) of 54% in patients who previously failed immune checkpoint inhibitor (ICI) therapy.The research revealed that Plinabulin works through GEF-H1-dependent dendritic cell maturation, with particularly strong responses in non-small cell lung cancer, head and neck squamous cell carcinoma, and Hodgkin lymphoma. Notably, Hodgkin lymphoma patients demonstrated durable responses exceeding 19 months despite having undergone 12-16 prior lines of therapy.

#BYSI BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

www.stocktitan.net/news/BYSI/beyond-spring-...

BeyondSpring and Merck's Triple Therapy Shows Promise in Advanced Lung Cancer After Immunotherapy Failure New Phase 2 data reveals triple combination therapy potential for resistant NSCLC patients. Key efficacy results from pembrolizumab-plinabulin-docetaxel study. See findings.

#BYSI BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

www.stocktitan.net/news/BYSI/beyond-spring-...

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update BeyondSpring (NASDAQ: BYSI) reported its Q1 2025 financial results and corporate updates. The company's lead drug Plinabulin has shown promising results in treating patients who failed PD-1/L1 inhibitors, with notable success in NSCLC and Hodgkin lymphoma. A Phase 1 study at MD Anderson showed extended response duration of over 19 months in heavily pretreated Hodgkin lymphoma patients. The company's SEED subsidiary is advancing its RBM39 degrader program, which achieved complete tumor regression in Ewing sarcoma models, with IND filing expected mid-2025. Financially, Q1 2025 saw increased expenses with R&D costs up 21% to $874,000 and G&A expenses up 30% to $1.74M, resulting in a net loss of $2.58M from continuing operations. BeyondSpring currently maintains approximately 40% ownership in SEED following a partial sale of Series A-1 Preferred Shares.

#BYSI BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/BYSI/beyond-spring-...

Just Released: BeyondSpring's Complete 2024 Financial Performance and Cancer Pipeline Updates Access comprehensive financial data and strategic updates from BeyondSpring's latest annual report. Key insights on cancer therapy pipeline and future outlook inside.

#BYSI BeyondSpring Files 2024 Annual Report on Form 10-K

www.stocktitan.net/news/BYSI/beyond-spring-...

BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate BeyondSpring monetizes SEED Therapeutics stake to fund promising Plinabulin trials, which demonstrated 89.3% disease control rate in NSCLC patients. Company retains 14.4% ownership.

#BYSI BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

www.stocktitan.net/news/BYSI/beyond-spring-...